Ali A. Azar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali A. Azar has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Aurelien Tripp
Division of Cell and Molecular Biology, The Institute of Cancer Research, London, UK
1 shared publication - Babak Jazayeri
Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
1 shared publication - Berthold Göttgens
Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
1 shared publication - Christopher Mapperley
Division of Cancer Biology, The Institute of Cancer Research, London, UK
1 shared publication - Corey Fyfe
Redona Therapeutics, Watertown, MA. USA
1 shared publication Derek George
Division of Cancer Biology, The Institute of Cancer Research, London, UK
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (33)
RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis
Acute myeloid leukemia (AML) is an aggressive hematological malignancy arising from hematopoietic stem and progenitor cells (HSPCs). Current treatments often fail to eradicate AML; therefore, new therapeutic strategies are essential. Here, we reveal that RNA terminal uridylyl transferase enzymes 4 and 7 (TUT4/7) are druggable therapeutic targets, whose genetic deletion suppresses AML growth, induces apoptosis, and improves the survival in leukemic mouse models. Notably, a preclinical TUT4/7 inhibitor promotes cell death in samples from patients with AML and synergizes with venetoclax. Mechanistically, TUT4/7 inactivation suppresses mevalonate pathway gene expression, compromising the cholesterol synthesis pathway. Current AML therapies often cause severe hematopoietic toxicity. Although Tut4/7 deletion results in inflammatory activation throughout the hematopoietic system, this is permissive to a normal life span and Tut4/7 deficiency does not compromise HSPC function. Together, these findings identify TUT4/7 as druggable targets, whose inactivation suppresses AML while sparing normal hematopoiesis. In combination with venetoclax, this represents a promising therapeutic strategy.
- 14 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (33)
Open AccessRNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis
Acute myeloid leukemia (AML) is an aggressive hematological malignancy arising from hematopoietic stem and progenitor cells (HSPCs). Current treatments often fail to eradicate AML; therefore, new therapeutic strategies are essential. Here, we reveal that RNA terminal uridylyl transferase enzymes 4 and 7 (TUT4/7) are druggable therapeutic targets, whose genetic deletion suppresses AML growth, induces apoptosis, and improves the survival in leukemic mouse models. Notably, a preclinical TUT4/7 inhibitor promotes cell death in samples from patients with AML and synergizes with venetoclax. Mechanistically, TUT4/7 inactivation suppresses mevalonate pathway gene expression, compromising the cholesterol synthesis pathway. Current AML therapies often cause severe hematopoietic toxicity. Although Tut4/7 deletion results in inflammatory activation throughout the hematopoietic system, this is permissive to a normal life span and Tut4/7 deficiency does not compromise HSPC function. Together, these findings identify TUT4/7 as druggable targets, whose inactivation suppresses AML while sparing normal hematopoiesis. In combination with venetoclax, this represents a promising therapeutic strategy.